Next date
None yet
Trials
14 active
23 in total · 18 in the EU
What this is
- How it works
- Interleukin-1 Receptor Antagonist FDA class
- Tested for
- Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
- Main trialPhase 3
- “A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis \[SJIA\] and Adult-onset Still's disease \[AOSD\]).”In the company’s words, NCT05814159 on ClinicalTrials.gov
- Other names
- Kineret
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials23
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 10 Dec 2025 | A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD) | |
| Phase 4Withdrawn | 30 Aug 2027 | A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF | |
| Phase 4Withdrawn | 30 Sep 2028 | An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD) | |
| Phase 3Terminated | 13 Feb 2019 | A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD) | |
| Phase 2/3Terminated | 13 Nov 2020 | Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. | |
| Phase 3Authorised | not given | Therapeutic approach in Colchicine-resistant Recurrent pEricarditis in children: an open-label randomized trial comparing Anakinra vs sTEroids | |
| Phase 2Ended | not given | Immunomodulatory effects of dexamethasone, tocilizumab and anakinra during experimental human endotoxemia: the DEDICATE-LPS study | |
| Phase 3Authorised | not given | Randomized controlled trial in patients on long-term colchicine with colchicine-resistant familial Mediterranean fever (FMF) to evaluate the efficacy of on-demand Anakinra treatment for painful attacks in patients who refuse continuous daily therapy (KIN-ATTACK-FMF). | |
| Phase 2/3Authorised | not given | Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post acute covid and immune system activation: the PRECISION double-blind, randomized clinical trial | |
| Phase 2Ended | not given | A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutaneous administration of anakinra in patients with cystic fibrosis (ANAKIN) | |
| Phase 2Ended | not given | PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease | |
| Phase 3Ended | not given | ANA4CKD - Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease stage 4-5 or kidney transplantation | |
| Phase 2Authorised | not given | Deciphering IL-1 mediated inflammation for the targeted treatment of dilated cardiomyopathy. | |
| Phase 2Ended | not given | Myocarditis Therapy with IL-1 inhibitor (MYTH-1): a double-blind, phase IIa, placebo controlled, randomized clinical trial to evaluate the efficacy and safety of anakinra in addition to standard of care for the treatment of virus-negative myocarditis. | |
| Phase 3Authorised | not given | ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RETREATMENT, IN PATIENTS WITH KAWASAKI DISEASE WHO FAILED TO RESPOND TO INITIAL STANDARD IVIG TREATMENT | |
| Phase 2Authorised | not given | Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial | |
| Phase 2Authorised | not given | Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study. | |
| Phase 4Authorised | not given | Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis | |
| Phase 2Authorised | not given | PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial | |
| Phase 3Authorised | not given | ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS. ANAPEM | |
| Phase 2Authorised | not given | Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment | |
| Phase 2Authorised | not given | THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation | |
| Phase 1/2Authorised | not given | IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026